OXUR.BR stock surges 11% in pre-market trading on May 13

OXUR.BR stock is making waves in pre-market trading on May 13, 2026, with a sharp 11.1% surge to €0.004 per share on EURONEXT. The Belgian biotech company Oxurion NV is trading at elevated volumes, with 465,886 shares changing hands compared to its average of 422,815. This pre-market momentum reflects renewed interest in the healthcare sector stock. Oxurion develops treatments for eye diseases, including its lead product JETREA for vitreomacular adhesion. Investors are watching closely as the company advances clinical trials for diabetic macular edema therapies.

Pre-Market Trading Activity and Volume Surge

OXUR.BR stock opened at €0.0036 and climbed to a day high of €0.004, marking a 10.1% intraday gain from the opening price. Trading volume reached 465,886 shares, representing a 1.10x relative volume spike above the 30-day average. This elevated activity signals strong institutional and retail interest in the biotech name.

The stock’s 52-week range spans from €0.0036 (low) to €0.084 (high), showing extreme volatility typical of early-stage biotech companies. The current price sits near the lower end of this range, suggesting potential recovery appeal for value-focused investors tracking OXUR.BR on Meyka for real-time updates.

Financial Metrics and Valuation Snapshot

Oxurion NV trades with a market cap of €280,394, reflecting its micro-cap status in the biotech space. The company has 70.1 million shares outstanding, diluted from recent capital raises. The stock’s PE ratio of 0.017 appears artificially low due to the company’s negative earnings profile and minimal revenue base.

Key financial headwinds include a current ratio of 0.17, indicating tight short-term liquidity. The company carries negative book value per share of -€1.41, typical for pre-revenue biotech firms burning cash on R&D. Revenue per share stands at just €0.00024, while the company reports an EPS of €2.23—a metric distorted by the minimal share price and accounting adjustments.

Clinical Pipeline and Strategic Focus

Oxurion’s pipeline centers on THR-149, a plasma kallikrein inhibitor in Phase II trials for diabetic macular edema (DME). The company also develops THR-687, an integrin antagonist also targeting DME in Phase II. These programs address a significant unmet need in ophthalmology, where DME affects millions globally.

The company maintains collaboration agreements with Bicycle Therapeutics, INC Research, and Galapagos NV, providing strategic partnerships and potential funding support. Earnings are scheduled for announcement on September 3, 2026, which could provide material updates on trial progress and cash runway. The company employs 110 full-time staff based in Leuven, Belgium.

Market Sentiment and Technical Positioning

The RSI of 45.61 suggests the stock is neither overbought nor oversold, sitting in neutral territory. The ADX of 57.04 indicates a strong downtrend is in place, despite today’s pre-market bounce. The CCI of -52.58 and Stochastic %K of 25 both signal oversold conditions, potentially explaining the intraday recovery.

Meyka AI rates OXUR.BR with a grade of B and a HOLD recommendation based on a score of 69.43. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. These grades are not guaranteed and we are not financial advisors. The company’s one-year performance shows a -94.3% decline, reflecting the brutal biotech selloff in 2025-2026.

Final Thoughts

OXUR.BR stock’s 11.1% pre-market surge reflects tactical buying in an oversold biotech name with clinical catalysts ahead. The elevated trading volume and technical oversold signals suggest short-term momentum, though the company’s negative financials and cash burn remain structural concerns. Oxurion’s pipeline in diabetic macular edema represents a meaningful therapeutic opportunity, but execution risk is high. The September earnings announcement will be critical for assessing cash runway and trial progress. Investors should monitor the stock’s ability to hold above €0.004 support and watch for clinical updates. This remains a speculative play suited only for risk-tolerant biotech investors.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.